RBC reiterates CollaGenex at outperform

CollaGenex Pharmaceuticals Inc. was reiterated at outperform, speculative risk, with a $19 price target by RBC Capital Markets analyst Ken Trbovich. IMS Health weekly total prescriptions for Oracea increased 16%. The current 12,636 prescriptions per month run rate exceeds RBC's 8,000 prescription monthly estimate for September. RBC's model assumes Oracea will reach about 6,500 prescriptions per week by December 2006. Shares of the Newtown, Pa.-based specialty pharmaceutical company were up 6 cents, or 0.47%, at $12.80. (Nasdaq: CGPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.